Trial of Cell-Based Therapy for High-Risk Lymphoma Leads to FDA Breakthrough ... 2024 — A new detailed analysis of a patient's second cancer after receiving CAR-T therapy for the initial cancer ...
Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.
Researchers at Cellectis leveraged gene editing to create a CAR T cell that acts in an IF/THEN system. Traditional methods to develop CAR T cells that use the patient’s cells introduce challenges ...